Korro Bio (NASDAQ:KRRO) Raised to Hold at Wall Street Zen

Posted by Brenda Bartman on Nov 9th, 2026

Korro Bio (NASDAQ:KRRO – Get Free Report) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

Several other research firms have also weighed in on KRRO. Weiss Ratings reiterated a “sell (d-)” rating on shares of Korro Bio in a report on Friday, October 2nd. Jefferies Financial Group set a $15.00 price target on shares of Korro Bio in a research report on Tuesday, October 6th. Finally, HC Wainwright reiterated a “buy” rating and issued a $15.00 price objective on shares of Korro Bio in a report on Tuesday, October 6th. Three investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Korro Bio presently has a consensus rating of “Moderate Buy” and a consensus target price of $16.50.

Read Our Latest Research Report on KRRO

Korro Bio Stock Performance

Shares of KRRO stock opened at $14.75 on Friday. The company’s 50-day moving average price is $11.62 and its 200-day moving average price is $12.06. The stock has a market cap of $217.27 million, a price-to-earnings ratio of -1.63 and a beta of 3.23. Korro Bio has a twelve month low of $5.20 and a twelve month high of $36.79.

Korro Bio (NASDAQ:KRRO – Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The company reported ($0.98) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.14) by $0.16. As a group, equities research analysts predict that Korro Bio will post -4.92 EPS for the current year.

Insider Buying and Selling

In other Korro Bio news, SVP Oliver Dolan sold 7,347 shares of the company’s stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $13.51, for a total value of $99,257.97. Following the transaction, the senior vice president owned 16,252 shares of the company’s stock, valued at $219,564.52. This represents a 31.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Jean Formela sold 28,468 shares of the stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $14.00, for a total transaction of $398,552.00. Following the transaction, the director directly owned 141,053 shares of the company’s stock, valued at approximately $1,974,742. This trade represents a 16.79% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders acquired 79,809 shares of company stock valued at $884,919 and sold 38,269 shares valued at $532,064. Corporate insiders own 4.80% of the company’s stock.

Institutional Investors Weigh In On Korro Bio

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. purchased a new position in shares of Korro Bio during the 3rd quarter worth approximately $54,000. Deutsche Bank AG purchased a new stake in Korro Bio in the second quarter valued at approximately $210,000. Hsbc Holdings PLC purchased a new stake in Korro Bio in the second quarter valued at approximately $233,000. North Star Investment Management Corp. raised its position in Korro Bio by 1,044.4% in the third quarter. North Star Investment Management Corp. now owns 20,600 shares of the company’s stock valued at $204,000 after purchasing an additional 18,800 shares during the period. Finally, Ieq Capital LLC acquired a new position in Korro Bio during the second quarter worth $280,000. 13.18% of the stock is owned by hedge funds and other institutional investors.

Korro Bio Company Profile

(Get Free Report)

Korro Bio, Inc is a clinical-stage biotechnology company developing RNA editing medicines for genetically driven diseases. The company’s approach is designed to make targeted changes to messenger RNA, potentially correcting or altering disease-related genetic instructions without permanently changing a patient’s DNA.

Korro Bio’s technology platform uses programmable oligonucleotides to guide RNA editing in specific cells and tissues. Its lead development program, KRRO-110, is being developed for alpha-1 antitrypsin deficiency, an inherited disorder caused by mutations in the SERPINA1 gene that can lead to liver and lung disease.